Hoth Therapeutics (NASDAQ:HOTH) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a $4.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. EF Hutton Acquisition Co. I raised shares of Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st. Benchmark reissued a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a report on Friday, October 11th.

Hoth Therapeutics Stock Performance

Shares of NASDAQ HOTH opened at $0.93 on Wednesday. The stock’s 50-day simple moving average is $0.84 and its 200-day simple moving average is $0.98. The firm has a market capitalization of $4.99 million, a PE ratio of -0.48 and a beta of 0.84. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.15. On average, sell-side analysts forecast that Hoth Therapeutics will post -1.18 earnings per share for the current fiscal year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.